EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis

Kristine Farmen, Doste R Mamand iD, Miguel Tofiño-Vian, Georgia Yfanti, Xiuming Liang, Houze Zhou, Vicky W Q Hou, Samir El Andaloussi, Oscar P B Wiklander iD, Federico Iovino iD

Journal of Extracellular Vesicles · 2026

DOI: 10.1002/jev2.70369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Kristine Farmen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Streptolysins, Meningitis, Pneumococcal, Extracellular Vesicles, Neuroinflammatory Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, European Society for Clinical Microbiology and Infectious Diseases (ESCMID), Wera Ekströms Stiftelse för Pediatrisk Forskning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacterial meningitis is a life‐threatening neurological disorder frequently caused by a Streptococcus pneumoniae (the pneumococcus) infection of the brain. Standard treatment consists of antibiotics to eliminate bacteria and dexamethasone to reduce inflammation. Despite this, mortality reaches 20% in treated individuals, and half of the survivors suffer long‐term neurological sequelae. This is largely due to the poor capacity of antibiotics to reach the brain and the lack of antimicrobial treatment capable of neutralizing the pneumococcal toxin pneumolysin (Ply). To address these limitations, we isolated extracellular vesicles (EVs) derived from human HEK293T cells and evaluated their therapeutic potential in pneumococcal meningitis. Alongside wild‐type EVs (WT.EVs), we bioengineered EVs to express RVG peptides (RVG.EV) for targeting neuronal acetylcholine receptors, signal incompetent IL‐6 signal transducer (IL‐6ST) decoy receptors (IL‐6.EV) to block the pro‐inflammatory signalling of IL‐6, or EVs expressing both RVG peptides and IL‐6ST (DB.EV). In vitro , all EVs reduced pneumococcal adhesion to neurons and mitigated cytotoxicity by binding and sequestering Ply. In a bacteremia‐derived pneumococcal meningitis model, EV treatment significantly increased the survival of the mice without affecting bacterial load in the brain or the periphery. Among all groups, RVG.EV treatment was most effective in reducing pro‐inflammatory cytokine release in the periphery and brain. These findings highlight the therapeutic potential of bioengineered EVs, particularly RVG peptides expressing EVs, as an adjunctive treatment for pneumococcal meningitis thanks to their (i) sequestration and neutralization of Ply, (ii) increased blood‐brain barrier crossing, and (iii) dampening of inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StreptolysinsMeningitis, PneumococcalExtracellular VesiclesNeuroinflammatory DiseasesAnimalsHumansMiceHEK293 CellsDisease Models, AnimalStreptococcus pneumoniaeBacterial ProteinsBioengineeringFemaleInterleukin-6Neurons

Stichwörter der Autor:innen

IL‐6RVGStreptococcus pneumoniaebioengineered extracellular vesiclesneuroinflammationneuronal protectionpneumococcal meningitispneumolysin

Substanzen

StreptolysinsplY protein, Streptococcus pneumoniaeBacterial ProteinsInterleukin-6

Autor:innen und Institutionen

  • Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Karolinska ATMP Center, Karolinska Institutet, Stockholm, Sweden.
  • Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
  • Biology Research Center, Research Center, University of Zakho, Zakho, Duhok, Kurdistan Region, Iraq.
  • Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Doste R Mamand, Oscar P B Wiklander, Federico Iovino

Förderung

  • Swedish Research Council
  • European Society for Clinical Microbiology and Infectious Diseases (ESCMID)
  • Wera Ekströms Stiftelse för Pediatrisk Forskning
  • Åhlén-stiftelsen
  • Magnus Bergvalls Stiftelse
  • Karolinska Institutet
  • HKH Crown Princess Lovisa's Association for Children's Healthcare
  • Stiftelsen Clas Groschinskys Minnesfond

Zitieren

APA

Farmen, K., Mamand, D. R., Tofiño-Vian, M., Yfanti, G., Liang, X., Zhou, H., Hou, V. W. Q., Andaloussi, S. E., Wiklander, O. P. B., & Iovino, F. (2026). Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70369

Vancouver

Farmen K, Mamand DR, Tofiño-Vian M, Yfanti G, Liang X, Zhou H, et al. Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70369

BibTeX
@article{Farmen2026,
  author = {Farmen, Kristine and Mamand, Doste R and Tofiño-Vian, Miguel and Yfanti, Georgia and Liang, Xiuming and Zhou, Houze and Hou, Vicky W Q and Andaloussi, Samir El and Wiklander, Oscar P B and Iovino, Federico},
  title = {Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  doi = {10.1002/jev2.70369}
}
Kostenlos starten →